Abstract:
L'invention concerne un composé allophanate modifié et porteur de fonctions acrylates, résultant de la réaction d'un allophanate particulier avec un ester issu de la réaction entre un acide choisi parmi l'acide acrylique et l'acide méthacrylique et au moins un polyol ne comprenant pas de groupement oxyalkylène ou (poly)oxyalkylène. L'invention concerne également l'utilisation de cet allophanate modifié pour la préparation d'une composition de revêtement hydrophobe réticulable, en par irradiation UV.
Abstract:
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
Abstract:
The invention relates to oligomeric and high-molecular conversion products of allophanic acid alkyl esters and allophanic acid aryl esters with nucleophilic compounds, and low-molecular, oligomeric and high-molecular compounds with allophanate side and/or terminal groups. The invention also relates to the use of said conversion products and/or the compounds in coating agents, adhesives and sealing materials, or for the production of films.
Abstract:
Die Erfindung betrifft ein Verfahren zur Herstellung von Polyisocyanat-Prepolymeren mit Allophanat-Struktureinheiten durch Verwendung von Zink-Verbindungen als Katalysatoren sowie deren Verwendung zur Herstellung von Polyurethanen und Polyharnstoffen.
Abstract:
The invention relates to positional isomer diethyloctandioldicarbamates and diethyloctandioldiallophanates, to a method for the production thereof and to the use thereof as synthetic building blocks and constituents of adhesives, luting compounds and coating materials.
Abstract:
The invention relates to diisocyanates of formula (I) in which the radicals have the following meanings: R , R : both radicals are a radical of formula (II) -CH2-CH2-CH2-CH2-CH2-CH2- (diisocyanates Ia); one radical is a radical of formula (II) and the other radical is a radical of formula (III) (diisocyanates Ib); both radicals are a radical of formula (III) (diisocyanates Ic); R is a 5 or 6 linked cycloalkyl radical in which up to 3 hydrogen atoms can be substituted by C1- to C4-alkyl radicals and one or two methylene units can be substituted by an oxygen atom and/or by a tertiary nitrogen atom which additionally carries a C1- to C4-alkyl radical. R can also be a C1- to C4-alkyl radical in which a hydrogen atom is substituted by a 5 or 6 linked cycloalkyl radical in which up to 3 hydrogen atoms can be substituted by C1- to C4-alkyl radicals and one or two methylene units can be substituted by an oxygen atom and/or by a tertiary nitrogen atom, said atom additionally carrying a C1- to C4-alkyl radical, and R is a pyrrolidone radical or a morpholine radical, whereby, with regard to both last-named radicals, the N-atom is bonded on the alkyl radical.
Abstract:
L'invention concerne le domaine des compositions de polyisocyanates pour la préparation de revêtements et d'adhésifs. La composition selon l'invention combine un composé polyisocyanate à motifs biuret, un composé diluant réactif polaire, protique, un de leurs composés d'addition et un composé diluant réactif aprotique. L'invention concerne également un procédé de préparation de la composition selon l'invention ainsi que son utilisation pour la préparation d'un revêtement ou d'un adhésif.
Abstract:
The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound.
Abstract:
Die Erfindung betrifft die Verwendung und Herstellung von Polyisocyanat-Prepolymeren mit Allophanat-Struktureinheiten in Formulierungen für Beschichtungen, Klebstoffe und Dichtstoffe.